Protagonist Therapeutics, Inc (PTGX) earnings date, results and what the price requires

    Nasdaq · SEC CIK 0001377121 · SEC filings checked Oct 17, 2026

    Next report
    Nov 5, 2026
    Estimated from reporting history (92-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
    Last close
    $128.75
    Polygon.io daily close, Oct 16, 2026. End of day, not live.
    Trailing diluted EPS
    $1.03
    Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025 · P/E 125.0

    Previous results (SEC filings)

    Quarter endedReportedRevenueNet incomeDiluted EPSSource
    Jun 30, 2026Aug 5, 2026$213.5M$162.8M$2.29Filing
    Mar 31, 2026May 5, 2026$56.4M$3.8M$0.05Filing
    Dec 31, 2025Feb 25, 2026$7.4M$-44.4M$-0.69Filing
    Sep 30, 2025Nov 6, 2025$4.7M$-39.3M$-0.62Filing
    Jun 30, 2025Aug 6, 2025$5.5M$-34.8M$-0.55Filing
    Mar 31, 2025May 6, 2025$28.3M$-11.7M$-0.19Filing
    Dec 31, 2024Feb 21, 2025$170.6M$131.7M$2.01Filing
    Sep 30, 2024Nov 7, 2024$4.7M$-33.2M$-0.54Filing

    What would Protagonist Therapeutics, Inc have to report for its valuation to change?

    At $128.75, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 60.6% a year, to $11.01. On that path the next quarter needs diluted EPS near $-1.00, against $-0.62 in the quarter ended Sep 30, 2025.

    Are you considering buying, or do you already own shares?

    Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.

    ResultOriginalYours
    Required EPS growth / year60.6%60.6%
    EPS needed in final year$11.01$11.01

    Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.

    Prepare for earnings across my investments — $399/month

    Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. PTGX goes in with your buy-or-wait comparison and assumptions preserved.

    Start Desk — $399/month

    Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.